Brokers Offer Predictions for IONS Q1 Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Equities research analysts at William Blair issued their Q1 2026 EPS estimates for Ionis Pharmaceuticals in a note issued to investors on Wednesday, February 19th. William Blair analyst M. Minter anticipates that the company will post earnings per share of ($1.17) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. William Blair also issued estimates for Ionis Pharmaceuticals’ Q2 2026 earnings at ($1.07) EPS, Q3 2026 earnings at ($0.89) EPS and Q4 2026 earnings at ($0.85) EPS.

Several other brokerages have also weighed in on IONS. Royal Bank of Canada reaffirmed an “outperform” rating and set a $70.00 price objective on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. Wells Fargo & Company cut their price target on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. Piper Sandler decreased their price objective on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Citigroup reduced their target price on Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Finally, StockNews.com lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $60.00.

Ionis Pharmaceuticals Stock Down 0.1 %

IONS opened at $31.85 on Monday. The company has a market capitalization of $5.06 billion, a PE ratio of -10.48 and a beta of 0.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 8.47 and a quick ratio of 8.82. Ionis Pharmaceuticals has a fifty-two week low of $30.23 and a fifty-two week high of $52.34. The business has a 50-day moving average of $33.41 and a 200-day moving average of $38.03.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The business had revenue of $227.00 million for the quarter, compared to the consensus estimate of $140.97 million. During the same period in the prior year, the business posted $0.12 earnings per share. Ionis Pharmaceuticals’s revenue for the quarter was down 30.2% compared to the same quarter last year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in IONS. Nicollet Investment Management Inc. raised its stake in shares of Ionis Pharmaceuticals by 1.5% in the third quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company’s stock worth $817,000 after acquiring an additional 294 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Ionis Pharmaceuticals by 3.1% in the third quarter. Amalgamated Bank now owns 9,957 shares of the company’s stock valued at $399,000 after purchasing an additional 300 shares in the last quarter. Itau Unibanco Holding S.A. raised its position in Ionis Pharmaceuticals by 40.9% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock worth $43,000 after purchasing an additional 314 shares during the last quarter. Xponance Inc. lifted its holdings in Ionis Pharmaceuticals by 1.7% during the 4th quarter. Xponance Inc. now owns 19,339 shares of the company’s stock worth $676,000 after buying an additional 318 shares in the last quarter. Finally, Vontobel Holding Ltd. boosted its position in Ionis Pharmaceuticals by 6.6% in the 4th quarter. Vontobel Holding Ltd. now owns 5,865 shares of the company’s stock valued at $205,000 after buying an additional 363 shares during the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Insider Buying and Selling at Ionis Pharmaceuticals

In other news, CEO Brett P. Monia sold 33,445 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $32.63, for a total value of $1,091,310.35. Following the completion of the transaction, the chief executive officer now owns 207,396 shares in the company, valued at approximately $6,767,331.48. The trade was a 13.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Patrick R. O’neil sold 6,165 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $31.62, for a total value of $194,937.30. Following the sale, the executive vice president now directly owns 57,452 shares of the company’s stock, valued at $1,816,632.24. This represents a 9.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 111,816 shares of company stock valued at $3,603,914. 2.71% of the stock is currently owned by company insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.